GZYJPCO(SH:603058)2024-07-08 08:17Financial Performance Forecast - The company expects a net profit attributable to shareholders of approximately CNY 74 million to CNY 79 million for the first half of 2024, representing an increase of CNY 45.81 million to CNY 50.81 million compared to the same period last year, which is a year-on-year increase of 162.47% to 180.21%[1]. - The net profit attributable to shareholders after deducting non-recurring gains and losses is expected to be approximately CNY 72 million to CNY 77 million, an increase of CNY 44.52 million to CNY 49.52 million year-on-year, reflecting a growth of 162.00% to 180.19%[5]. - The net profit for the same period last year was CNY 28.19 million, and the net profit after deducting non-recurring gains and losses was CNY 27.48 million[7]. - The basic earnings per share for the same period last year was CNY 0.068 per share[8]. Revenue Growth Factors - The significant increase in profit is attributed to a 70% year-on-year growth in revenue from the medical cannabis business of the company's Australian subsidiary for the first half of 2024[9]. - Revenue from the company's cigarette label printing business outside Guizhou province also experienced a net increase during the same period[9]. - The company did not face the impact of the cigarette label QR code upgrade and revision that affected profitability in the second quarter of 2023, which contributed to the improved performance in 2024[9]. Performance Forecast Reliability - The performance forecast has not been audited by a registered accountant[2]. - There are currently no major uncertainties that could affect the accuracy of this performance forecast[10]. - The forecast data is preliminary and the specific financial data will be disclosed in the official 2024 semi-annual report[11].